Posterior Fossa Ependymoma H3 K27-mutant: an Integrated Radiological and Histomolecular Tumor Analysis
Overview
Authors
Affiliations
Posterior fossa group A ependymomas (EPN_PFA) are characterized by a loss of H3 K27 trimethylation due to either EZHIP overexpression or H3 p.K27M mutation, similar to H3 K27-altered diffuse midline gliomas (DMG), but in reverse proportions. Very little data is available in the literature concerning H3 K27M-mutant EPN_PFA. Here, we retrospectively studied a series of nine pediatric tumors initially diagnosed as H3 K27M-mutant EPN_PFA to compare them to EZHIP-overexpressing EPN_PFA in terms of radiology, follow-up, histopathology, and molecular biology (including DNA-methylation profiling). Seven tumors clustered within EPN_PFA by DNA-methylation analysis and t-distributed stochastic neighbor embedding. Among the two remaining cases, one was reclassified as a DMG and the last was unclassified. H3 K27M-mutant EPN_PFA cases were significantly older than their counterparts with an EZHIP overexpression. Radiological and histopathological central review of our seven H3 K27M-mutant EPN_PFA cases found them to be similar to their counterparts with an EZHIP overexpression. Sequencing analyses revealed HIST1H3B (n = 2), HIST1H3C (n = 2), H3F3A (n = 1), and HIST1H3D (n = 1) K27M mutations (no sequencing analysis available for the last case which was immunopositive for H3K27M). Consequently, HIST1H3C/D mutations are more frequently observed in EPN_PFA than in classic pontine DMG, H3K27-mutant. Overall survival and event-free survival of EZHIP-overexpressing and H3 K27M-mutant EPN_PFA were similar. After surgery and radiation therapy, 5/7 patients were alive at the end of the follow-up. In summary, the diagnosis of EPN_PFA must include tumor location, growth pattern, Olig2 expression, and DNA-methylation profiling before it can be differentiated from DMG, H3 K27-altered.
Advances in molecular prognostication and treatments in ependymoma.
Bakes E, Cheng R, Manucat-Tan N, Ramaswamy V, Hansford J J Neurooncol. 2025; .
PMID: 39757304 DOI: 10.1007/s11060-024-04923-9.
Rapid intraoperative amplicon sequencing of CNS tumor markers.
Evers M, Brandl B, Rohrandt C, Kubelt-Kwamin C, Muller F, Danso D Comput Struct Biotechnol J. 2024; 26:51-57.
PMID: 39606159 PMC: 11600771. DOI: 10.1016/j.csbj.2024.11.007.
Xu C, Beers C, Lu J, Hann C, Ramos R Front Neurol. 2024; 15:1482832.
PMID: 39582680 PMC: 11581895. DOI: 10.3389/fneur.2024.1482832.
Sanchez-Guixe M, Muinos F, Pinheiro-Santin M, Gonzalez-Huici V, Rodriguez-Hernandez C, Avgustinova A Cancer Discov. 2024; 14(6):953-964.
PMID: 38501975 PMC: 11145171. DOI: 10.1158/2159-8290.CD-23-1186.
Tauziede-Espariat A, Metais A, Mariet C, Castel D, Grill J, Saffroy R Brain Pathol. 2023; 34(1):e13181.
PMID: 37331375 PMC: 10711257. DOI: 10.1111/bpa.13181.